Discovery of a potent FKBP38 agonist that ameliorates HFD-induced hyperlipidemia
Acta Pharmaceutica Sinica B
;
(6): 3542-3552, 2021.
Article
Dans Anglais
| WPRIM
| ID: wpr-922423
ABSTRACT
The mammalian target of rapamycin (mTOR)-sterol regulatory element-binding proteins (SREBPs) signaling promotes lipogenesis. However, mTOR inhibitors also displayed a significant side effect of hyperlipidemia. Thus, it is essential to develop mTOR-specific inhibitors to inhibit lipogenesis. Here, we screened the endogenous inhibitors of mTOR, and identified that FKBP38 as a vital regulator of lipid metabolism. FKBP38 decreased the lipid content
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Anglais
Texte intégral:
Acta Pharmaceutica Sinica B
Année:
2021
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS